Point-of-Care Production of CAR-T Cells
暂无分享,去创建一个
[1] H. Einsele,et al. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma , 2021, Gene Therapy.
[2] A. Wick,et al. Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR , 2020, Cancers.
[3] M. Juan,et al. Cell Banking of HEK293T cell line for clinical-grade lentiviral particles manufacturing , 2020, Translational Medicine Communications.
[4] S. Rives,et al. Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial , 2020, Frontiers in Immunology.
[5] P. Dreger,et al. Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients , 2020, Molecular therapy. Methods & clinical development.
[6] L. Sellner,et al. Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells , 2019, Cancer Immunology, Immunotherapy.
[7] A. Ho,et al. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol , 2019, BMJ Open.
[8] M. Lowdell,et al. Manufacturing chimeric antigen receptor T cells: issues and challenges. , 2019, Cytotherapy.
[9] S. Rives,et al. Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions , 2018, Molecular therapy. Methods & clinical development.
[10] A. Ho,et al. Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients , 2018, Front. Immunol..